Navigation Links
AMT Makes Important Advance in the Development of its Gene Therapy for Hemophilia B -Company Accesses Technology to Prevent Immune Response
Date:6/9/2008

AMSTERDAM, The Netherlands, June 10 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a license from 'TIGET' San Raffaele Telethon Institute For Gene Therapy, Italy, to use their micro-RNA technology to prevent immune responses against gene therapy for Hemophilia B. This technology enables AMT to accelerate the development of AMT-060 (AMT's AAV-based gene therapy for this seriously debilitating disease).

Hemophilia B occurs in 1 in 30,000 males and results in severe internal and external bleeding. The disease is caused by defective blood clotting due to an absence of clotting factor Factor IX. Gene therapy can be used to introduce the gene that produces Factor IX and thereby repair blood clotting. AMT will use the TIGET technology to prevent an immune response against the newly formed Factor IX, which the patient's body may recognize as being foreign.

Formalizing relationship with leading micro-RNA research group of professor Naldini

Ronald Lorijn, CEO of AMT said: "We are very excited to have licenced this groundbreaking technology, which has been shown to prevent immune responses effectively. Access to TIGET's micro-RNA technology perfectly complements our gene therapy approach to cure hemophilia B with a single treatment."

TIGET is very satisfied as this agreement represents an important development of the discoveries made by Prof. Luigi Naldini, Co-Director of TIGET and his collaborator Dr. Brian Brown, and that it will foster further industrial collaborations aimed at moving these innovative solutions from the research to the clinic.

Micro-RNA inhibition

Luigi Naldini and Brian Brown of TIGET have demonstrated in mouse models that naturally occurring micro-RNAs can be exploited to stringently regulate the expression of genes delivered by vectors used in gene therapy.

With this approach expression of the Factor IX gene can be selectively blocked by AMT in immune stimulating cells thus preventing the development of an immune response, and thereby enabling full effectiveness of the gene therapy for Hemophilia B.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases that are caused by one faulty gene. AMT currently has a product pipeline with seven products at different stages of development.

About TIGET

The San Raffaele Telethon Institute for Gene Therapy (HSR-TIGET) is a joint-venture between the San Raffaele Scientific Institute and the Telethon Foundation for the implementation of basic, pre-clinical and clinical research for genetic diseases. The mission of the Institute is to perform cutting edge science in the field of gene therapy and to promote the translation of basic discoveries into therapeutic advances. The genetic diseases, which are presently under investigation include primary immunodeficiencies, lysosomal storage disorders, type I diabetes, hemophilia.

In addition, a primary goal of TIGET research is to improve the efficiency and safety of gene transfer by advancing the development and applications of lentiviral vector technology. For this research TIGET also received funding from the European Union (VIth Framework Program: Project RIGHT).

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Web Portal Makes Organ Donation Easy
2. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
3. NanoLogix Inc. Appoints Director of IP and Makes Progress on Rapid Anthrax Detection
4. Argonne researcher studies what makes quantum dots blink
5. Modifying an anti-cancer drug makes it more specific
6. NanoLogix, Inc. Makes Stock Pick List
7. Pharsight Makes Strong Contribution to Inaugural American Conference on Pharmacometrics
8. CSCs Dr. Robert M. Wah Makes Top 10 in 50 Most Powerful Physician Executives List
9. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
10. 454 Sequencing(TM): Science Paper Suggests That Structural Variation Plays an Important Role in Genetic Variation
11. Stem Cell Science Holds Opportunities as Important Tool for Diabetes Research Beyond Cell-Based Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... MONICA, Calif. , June 23, 2016  The Prostate Cancer Foundation ... pioneer increasingly precise treatments and faster cures for prostate cancer. Members of the ... institutions across 15 countries. Read More About the Class ... ... ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
Breaking Biology Technology:
(Date:5/16/2016)... YORK , May 16, 2016   EyeLock ... solutions, today announced the opening of an IoT Center ... to strengthen and expand the development of embedded iris ... an unprecedented level of convenience and security with unmatched ... authenticate one,s identity aside from DNA. EyeLock,s platform uses ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):